Smuggling Erectile Dysfunction Chemicals
Tadalafil Found in Passenger's Luggage Had Estimated Domestic Value is $179,000
U.S. Customs and Border Protection (CBP) officers at Los Angeles International Airport (LAX), Tom Bradley International Terminal stopped the attempt to smuggle over 63.3 pounds of tadalafil, the main chemical component of erectile dysfunction drugs. The substance with an estimated domestic value of $179,000 was seized on January 6.
CBP officers referred a 40 year-old Korean national, for secondary baggage examination. During their inspection of his two carry-on luggage, CBP officers noticed several heat sealed pouches containing a white powdery substance. The passenger claimed the powder was a Chinese herb.
The pouches were detained and samples of the substance were sent to Laboratories and Scientific Services (LSS), CBP’s scientific arm. LSS chemists identified the powder as tadalafil. A filed application or approval is required to introduce a new drug into interstate commerce which the passenger lacked.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Individualized cancer therapy soon to be faster and more effective thanks to artificial intelligence - Intelligent and automated production of therapeutics in the future
EMA to relocate to Amsterdam - Working with Dutch government to ensure successful move by end of March 2019
Wyeth and Zealand Pharma Advance the First Orally Available Gap Junction Modifier into Phase I Clinical Trials
Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
Sinochem To Acquire Butachlor and Alachlor Businesses In Certain Asian Countries And India From Monsanto
